Shanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System

Bulletin Express

Oct 31

Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

According to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.

The company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137849417"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137849417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137849417?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137849417","market":"hk","top_or_hot":-1,"title":"Shanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.</p>\n<p>According to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.</p>\n<p>The company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-31 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.</p>\n<p>According to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.</p>\n<p>The company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1137849417","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137849417","pubTimestamp":1761843458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"上海生物心脏(2185)宣布Iberis获得英国MHRA注册®RDN系统","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.\nAccording to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.\nThe company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}